Moderna, Inc.
MRNA
$26.26
-$0.46-1.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.56% | -53.40% | -43.18% | -51.48% | -65.06% |
| Total Other Revenue | 4.20% | -28.25% | -69.53% | -73.10% | -80.17% |
| Total Revenue | -38.35% | -52.75% | -44.29% | -52.60% | -65.78% |
| Cost of Revenue | -33.96% | -37.02% | -37.27% | -7.00% | -3.19% |
| Gross Profit | 27.73% | -3.01% | -15.61% | -276.43% | -160.39% |
| SG&A Expenses | -26.75% | -24.21% | -11.07% | 12.71% | 29.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.90% | -35.23% | -34.04% | -4.50% | 0.59% |
| Operating Income | 27.44% | 6.94% | -1.05% | -1,003.51% | -206.46% |
| Income Before Tax | 29.07% | 8.50% | 0.17% | -629.58% | -195.26% |
| Income Tax Expenses | -104.20% | -105.96% | -111.63% | 494.60% | 353.70% |
| Earnings from Continuing Operations | 43.75% | 24.46% | 35.83% | -586.08% | -224.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.75% | 24.46% | 35.83% | -586.08% | -224.75% |
| EBIT | 27.44% | 6.94% | -1.05% | -1,003.51% | -206.46% |
| EBITDA | 22.43% | -3.81% | -9.05% | -568.84% | -188.13% |
| EPS Basic | 44.29% | 25.00% | 36.51% | -601.73% | -227.99% |
| Normalized Basic EPS | 29.98% | 8.80% | 2.04% | -631.06% | -195.82% |
| EPS Diluted | 44.31% | 25.16% | 37.42% | -662.79% | -235.26% |
| Normalized Diluted EPS | 30.00% | 8.55% | 4.67% | -737.43% | -201.27% |
| Average Basic Shares Outstanding | 0.98% | 0.46% | -0.07% | -0.91% | -2.06% |
| Average Diluted Shares Outstanding | 0.97% | -0.77% | -0.76% | -3.81% | -6.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |